Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04669054
Other study ID # RECHMPL20_0665
Secondary ID
Status Completed
Phase
First received
Last updated
Start date December 1, 2020
Est. completion date July 30, 2021

Study information

Verified date October 2021
Source University Hospital, Montpellier
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The mental health of the French population in response to covid-19 pandemic is of concern. Health professionals are prone to more mental disorders due to their direct exposure to the pandemic consequences. Indeed, compared to general population, health care workers face enormous in the current health situation, especially those who may be in contact with suspected or confirmed cases (risk of infection, inadequate protection, loss of control, lack of experience in managing the diseases, overwork, stigma, lack of support). Thus, it seems interesting to describe the psychological state of hospital interns during this pandemic.


Recruitment information / eligibility

Status Completed
Enrollment 102
Est. completion date July 30, 2021
Est. primary completion date May 30, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion criteria: - Being a DES intern (Occitanie-Est) - Being on internship as of November 1, 2020 Exclusion criteria: - Refusal to participate

Study Design


Locations

Country Name City State
France University hospital Montpellier

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Montpellier

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Depressive Symptomatology (PHQ-9) evaluation of the participant depressive symptomatology based on the PHQ-9 scale. The PHQ-9 total score ranges from 0 to 27. A score between 0 and 4 indicates absence of depression; a score between 5 and 9 indicates mild depression; a score between 10 and 14 indicates moderate depression; score between 15 and 19 indicates moderately severe depression and score between 20 and 27 indicates sever depression. at 5 months (6 months of internship)
Primary Depressive Symptomatology (PHQ-9) evaluation of the participant depressive symptomatology based on the PHQ-9 scale. The PHQ-9 total score ranges from 0 to 27. A score between 0 and 4 indicates absence of depression; a score between 5 and 9 indicates mild depression; a score between 10 and 14 indicates moderate depression; score between 15 and 19 indicates moderately severe depression and score between 20 and 27 indicates sever depression. at inclusion (1 month of internship)
Primary Depressive Symptomatology (PHQ-9) evaluation of the participant depressive symptomatology based on the PHQ-9 scale. The PHQ-9 total score ranges from 0 to 27. A score between 0 and 4 indicates absence of depression; a score between 5 and 9 indicates mild depression; a score between 10 and 14 indicates moderate depression; score between 15 and 19 indicates moderately severe depression and score between 20 and 27 indicates sever depression. at 2 months (3 months of internship)
Secondary Sleep evaluation with the Insomnia Severity Index (ISI) sleep quality evaluation based on the ISI score. The ISI total score ranges from 0 to 28. A score between 0 and 7 indicates an absence of insomnia; a score between 8 and 14 indicates sub-threshold insomnia; a score between 15 and 21 indicates moderate insomnia and a score between 22 and 28 indicates severe insomnia. at inclusion (1 month of internship)
Secondary Sleep evaluation with the Insomnia Severity Index (ISI) sleep quality evaluation based on the ISI score. The ISI total score ranges from 0 to 28. A score between 0 and 7 indicates an absence of insomnia; a score between 8 and 14 indicates sub-threshold insomnia; a score between 15 and 21 indicates moderate insomnia and a score between 22 and 28 indicates severe insomnia. at 2 months (3 months of internship)
Secondary Sleep evaluation with the Insomnia Severity Index (ISI) sleep quality evaluation based on the ISI score. The ISI total score ranges from 0 to 28. A score between 0 and 7 indicates an absence of insomnia; a score between 8 and 14 indicates sub-threshold insomnia; a score between 15 and 21 indicates moderate insomnia and a score between 22 and 28 indicates severe insomnia. at 5 months (6 months of internship)
Secondary Anxiety with the Generalised Anxiety Disorder Assessment (GAD-7) anxiety evaluation based on the GAD-7 score. The GAD-7 total score ranges from 0 to 21. Scores of 5, 10, and 15 represent cut-points for mild, moderate, and severe anxiety, respectively. at inclusion (1 month of internship)
Secondary Anxiety with the Generalised Anxiety Disorder Assessment (GAD-7) anxiety evaluation based on the GAD-7 score. The GAD-7 total score ranges from 0 to 21. Scores of 5, 10, and 15 represent cut-points for mild, moderate, and severe anxiety, respectively. at 2 months (3 months of internship)
Secondary Anxiety with the Generalised Anxiety Disorder Assessment (GAD-7) anxiety evaluation based on the GAD-7 score. The GAD-7 total score ranges from 0 to 21. Scores of 5, 10, and 15 represent cut-points for mild, moderate, and severe anxiety, respectively. at 5 months (6 months of internship)
Secondary Psychological pain assessed with visual analogue scale (VAS) assessment of the psychological pain. The VAS ranges from 0 (none) to 10 (maximum pain). at inclusion (1 month of internship)
Secondary Psychological pain assessed with visual analogue scale (VAS) assessment of the psychological pain. The VAS ranges from 0 (none) to 10 (maximum pain). at 2 months (3 months of internship)
Secondary Psychological pain assessed with visual analogue scale (VAS) assessment of the psychological pain. The VAS ranges from 0 (none) to 10 (maximum pain). at 5 months (6 months of internship)
Secondary Physical pain assessed with visual analogue scale (VAS) assessment of the physical pain. The VAS ranges from 0 (none) to 10 (maximum pain). at inclusion (1 month of internship)
Secondary Physical pain assessed with visual analogue scale (VAS) assessment of the physical pain. The VAS ranges from 0 (none) to 10 (maximum pain). at 2 months (3 months of internship)
Secondary Physical pain assessed with visual analogue scale (VAS) assessment of the physical pain. The VAS ranges from 0 (none) to 10 (maximum pain). at 5 months (6 months of internship)
Secondary Suicidal ideation assessed with visual analogue scale (VAS) assessment of the suicidal ideation. The VAS ranges from 0 (none) to 10 (maximum ideation). at inclusion (1 month of internship)
Secondary Suicidal ideation assessed with visual analogue scale (VAS) assessment of the suicidal ideation. The VAS ranges from 0 (none) to 10 (maximum ideation). at 2 months (3 months of internship)
Secondary Suicidal ideation assessed with visual analogue scale (VAS) assessment of the suicidal ideation. The VAS ranges from 0 (none) to 10 (maximum ideation). at 5 months (6 months of internship)
Secondary Anger assessed with the State Anger Expression Inventory (STAXI - state) anger assessment with the STAXI state scale. The total score ranges from 0 to 50. The higher the score the higher the anger expression. at 2 months (3 months of internship)
Secondary Anger assessed with the State Anger Expression Inventory (STAXI - state) anger assessment with the STAXI state scale. The total score ranges from 0 to 50. The higher the score the higher the anger expression. at 5 months (6 months of internship)
Secondary Anger assessed with the State Anger Expression Inventory (STAXI - state) anger assessment with the STAXI state scale. The total score ranges from 0 to 50. The higher the score the higher the anger expression. at inclusion (1 month of internship)
Secondary Stressful Event Impact (Horowitz scale) assessement of stressful event impact with the Horowitz scale. The total score ranges from 0 to 45. The higher the score the higher the trauma at inclusion (1 month of internship)
Secondary Stressful Event Impact (Horowitz scale) assessement of stressful event impact with the Horowitz scale. The total score ranges from 0 to 45. The higher the score the higher the trauma at 2 months (3 months of internship)
Secondary Stressful Event Impact (Horowitz scale) assessement of stressful event impact with the Horowitz scale. The total score ranges from 0 to 45. The higher the score the higher the trauma at 5 months (6 months of internship)
Secondary Psychotropic drugs use assessement of the psychotropic drugs use increase at inclusion (1 month of internship)
Secondary Psychotropic drugs use assessement of the psychotropic drugs use increase at 5 months (6 months of internship)
Secondary Psychotropic drugs use assessement of the psychotropic drugs use increase at 2 months (3 months of internship)
Secondary Tobacco consumption assessement of the tobacco consumption increase at 2 months (3 months of internship)
Secondary Tobacco consumption assessement of the tobacco consumption increase at inclusion (1 month of internship)
Secondary Tobacco consumption assessement of the tobacco consumption increase at 5 months (6 months of internship)
Secondary Alcohol consumption assessement of the alcohol consumption increase at 2 months (3 months of internship)
Secondary Alcohol consumption assessement of the alcohol consumption increase at inclusion (1 month of internship)
Secondary Alcohol consumption assessement of the alcohol consumption increase at 5 months (6 months of internship)
Secondary Illicit substances use assessement of the illicit substances use increase at inclusion (1 month of internship)
Secondary Illicit substances use assessement of the illicit substances use increase at 2 months (3 months of internship)
Secondary Illicit substances use assessement of the illicit substances use increase at 5 months (6 months of internship)
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05777044 - The Effect of Hatha Yoga on Mental Health N/A
Recruiting NCT04680611 - Severe Asthma, MepolizumaB and Affect: SAMBA Study
Recruiting NCT04977232 - Adjunctive Game Intervention for Anhedonia in MDD Patients N/A
Recruiting NCT04043052 - Mobile Technologies and Post-stroke Depression N/A
Completed NCT04512768 - Treating Comorbid Insomnia in Transdiagnostic Internet-Delivered Cognitive Behaviour Therapy N/A
Recruiting NCT03207828 - Testing Interventions for Patients With Fibromyalgia and Depression N/A
Completed NCT04617015 - Defining and Treating Depression-related Asthma Early Phase 1
Recruiting NCT06011681 - The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
Completed NCT04476446 - An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives Phase 3
Recruiting NCT02783430 - Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease Phase 2/Phase 3
Recruiting NCT05563805 - Exploring Virtual Reality Adventure Training Exergaming N/A
Completed NCT04598165 - Mobile WACh NEO: Mobile Solutions for Neonatal Health and Maternal Support N/A
Completed NCT03457714 - Guided Internet Delivered Cognitive-Behaviour Therapy for Persons With Spinal Cord Injury: A Feasibility Trial
Recruiting NCT05956912 - Implementing Group Metacognitive Therapy in Cardiac Rehabilitation Services (PATHWAY-Beacons)
Completed NCT05588622 - Meru Health Program for Cancer Patients With Depression and Anxiety N/A
Recruiting NCT05234476 - Behavioral Activation Plus Savoring for University Students N/A
Active, not recruiting NCT05006976 - A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study N/A
Enrolling by invitation NCT03276585 - Night in Japan Home Sleep Monitoring Study
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A